This possibility is supported by reports indicating that selective chemical probes targeting BRD9 (inhibitors) when applied in NSCLC cell lines, significantly increased sensitivity to EGFR-TKIs [56]. The gene discussed is BRD9; the disease is non-small cell lung carcinoma.